List view / Grid view

Bristol-Myers Squibb Company

 

news

Bristol-Myers Squibb and Calibr sign worldwide agreement focused on new treatment approaches for fibrotic diseases

5 January 2015 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and the California Institute for Biomedical Research (Calibr) announced they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration...

news

Bristol-Myers Squibb announces dividend

10 December 2014 | By Bristol-Myers Squibb Company

The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $.10 par value Common Stock of the corporation...

news

Analyses from Phase IIIb Study provide additional data in earlier use of Orencia (abatacept) plus Methotrexate (MTX)

18 November 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase IIIb AVERT (Assessing Very Early Rheumatoid arthritis Treatment) trial that investigated the use of Orencia plus methotrexate (MTX) in biologic and MTX-naïve citrullinated protein (CCP)-positive early moderate to severe rheumatoid arthritis (RA) patients...

news

Study comparing Opdivo (nivolumab) to chemotherapy in treatment naïve advanced melanoma patients marks first PD-1 immune checkpoint inhibitor to demonstrate a survival benefit in a Phase 3 trial

17 November 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced results from CheckMate -066, a Phase 3 randomized double blind study, comparing Opdivo, an investigational PD-1 immune checkpoint inhibitor, to the chemotherapy dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type advanced melanoma (n=418)...

news

ALLY Trial demonstrates high cure rates for investigational daclatasvir and sofosbuvir combination among genotype 3 hepatitis C patients

10 November 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced late-breaking data from the landmark ALLY Trial investigating a ribavirin-free 12-week regimen of daclatasvir (DCV) in combination with sofosbuvir (SOF) in genotype 3 hepatitis C (HCV) patients, a patient population that has emerged as one of the most difficult to treat...

news

Bristol-Myers Squibb to acquire Galecto Biotech AB and its novel Galectin-3 Inhibitor in development for Idiopathic Pulmonary Fibrosis

4 November 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and Galecto Biotech AB have announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in…

news

Bristol-Myers Squibb and Lonza expand biologics manufacturing agreement

31 October 2014 | By

Bristol-Myers Squibb Company and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.